+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: AstraZeneca

  • ID: 5357339
  • Company Profile
  • January 2021
  • 87 pages
  • Datamonitor Healthcare
  • Astrazeneca PLC
The publisher explores AstraZeneca’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - AstraZeneca is poised for continued growth, driven by its oncology portfolio and strong presence in high-growth emerging markets like China.
  • Key themes - [1] AstraZeneca’s oncology portfolio - Tagrisso, Imfinzi, Lynparza, among others - grew 44% in 2019 and should sustain robust growth rates over the forecast period [2] Leading position in Rest of World markets, such as China, provides AstraZeneca with a strong foothold to drive future growth as these emerging markets should grow quicker than established markets [3] Upcoming product launches of Enhertu, roxadustat, and tezepelumab, which each have the potential to be blockbusters.
Model updates (6 November 2020)
  • Tagrisso forecast adjusted lower due to high market penetration in first-line NSCLC
  • Imfinzi forecast adjusted lower in Japan
  • Lynparza forecast adjusted lower in Japan
  • Enhertu forecast adjusted lower due to removal of estimates in 5EU as Daiichi Sankyo commercializes in those markets.
Model updates (3 August 2020)
  • Pulmicort forecast adjusted lower due to negative impact of COVID-19 in China
  • Imfinzi forecast adjusted lower.
Model updates (21 May 2020)
  • Tagrisso forecast adjusted higher due to recent results of ADAURA trial in adjuvant NSCLC
  • Calquence forecast adjusted higher due to supplemental approval in CLL/SLL
  • Farxiga forecast adjusted lower due to complete response letter in type 1 diabetes
  • Koselugo forecast added.
Model updates (9 March 2020)
  • Tagrisso sales adjusted higher due to continued growth in first-line non-small cell lung cancer
  • DS-8201 name changed to Enhertu; forecast adjusted due to launch timing and revenue recognition guidance (royalties from Daiichi will not be recognized as product sales)
  • Symbicort forecast adjusted higher due to launch of authorized generic in the US, and strength in Rest of World
  • Pulmicort forecast adjusted higher due to higher demand in Rest of World
  • Fasenra forecast adjusted higher due to continued market share gains in severe, uncontrolled asthma
  • Epanova forecast removed due to termination of Phase IIII STRENGTH trial.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll